We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
the YGEN thread is now open on advfn thanks to TWIX
it is on lse, but no one has set up a thread on advfn as of yet, i would if i knew how.
Still not available
LSE:YGEN added to my monitor still gives me unknown share.
You have to press the Go button as well.
Nothing comes up when i put YGEN in
Yourgene Health PLC Change of Name to Yourgene Health plc
07/11/2018 7:00am
UK Regulatory (RNS & others)
Premaitha (LSE:NIPT)
Intraday Stock Chart
Today : Wednesday 7 November 2018
TIDMYGEN
RNS Number : 5273G
Yourgene Health PLC
07 November 2018
Premaitha Health plc
("Premaitha" or the "Group")
Change of Name to Yourgene Health plc
&
Change of Website Address
Manchester, UK - 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc ("Yourgene Health").
Further to the special resolution approved at the Group's Annual General Meeting on 25 October 2018, the Group's name has been changed to Yourgene Health plc and trading in the Group's shares under the new name and TIDM, "YGEN", will commence at 8.00 a.m. today. The Group's website is now available at www.yourgene-health.com.
The change of name reflects the Group's broadened product development and research service capabilities which extend across the lifecycle of DNA test development and commercialisation.
Yourgene Health's ongoing strategic priorities include:
-- developing and commercialising genetic products and services that positively impact human health;
-- driving worldwide sales of the Group's non-invasive prenatal testing ("NIPT") products and services by targeting further expansion through direct and key distribution channels to expand the geographic footprint;
-- continuing to offer highly customer-focused NIPT products and services which support all types of customer - irrespective of size, geography and market maturity - in partnership with leading DNA technology providers;
-- leveraging the Group's technical and regulatory expertise and partnerships to extend its genetic testing offering into complementary areas of reproductive health and oncology, both with owned intellectual property and as a third-party collaborator; and
-- supporting diagnostic majors and bioinformatics specialists with in vitro diagnostic product contract development partnerships.
Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name Yourgene Health plc.
Lyn Rees, Chief Executive Officer of Yourgene Health, commented: "Our change of name to Yourgene Health marks the beginning of an exciting new period for the Group. It reflects our broadened capabilities within the genetic testing universe and the combining of the Premaitha and Yourgene Bioscience businesses.
"Within the NIPT segment, we are aggressively targeting further expansion through distribution and licensing partnerships. The consolidated Group is now well-placed to deliver services to a global market and maximise its revenue potential.
"Our technical expertise in genetic test development, partnerships with DNA technology majors and expanding global footprint also put us in a strong position to develop additional products both within reproductive health and oncology.
"I look forward to providing further updates on the commercialisation of the Group as we expand organically, through distribution and licensing agreements, and via third party partnerships."
It looks like on LSE the YGEN ticker is up and running, so maybe we have to move any further chat over there?
Further to the special resolution approved at the Group's Annual General Meeting on 25 October 2018, the Group's name has been changed to Yourgene Health plc and trading in the Group's shares under the new name and TIDM, "YGEN", will commence at 8.00 a.m. today.
The Group's website is now available at www.yourgene-health.com.
Their website has gone (for me, anyway). Anyone know what the new one is called??
on ADVFN site but not on LSE?
RNS sounds very possitive hopefully more news to come in the next week or so!
As from today.
https://www.premaitha.com/company/yourgene-bioscience
I know they bought these guys a while back, a name change can only be a positive thing IMO
Im with Barclays and nothing has changed yet!
My trading platform has the name Yourgene instead of Premaithia. Has anyone noticed the name change?
Cheers for this.
The Investor meeting on the 16th suggested an updated trading statement by the 25th October and then an updated broker's report in 'early' November. Obviously the former was more of a recycled statement but I would have imagined some development to initiate the latter (e.g. new contract/product or TMO deal).
It would be difficult for them to back-stop everything to the 3rd Dec and I genuinely hope that's not the intention.
For me Peter Collins to step down immediately was very strange. It would seem for Peter Collins to leave in the midst of negotiations with TMO as well as potential oncology/reproductive health contracts given his past history in brokering these deals and in commercial negotiations. Similarly it would be strange for him not to stay on at least for a few more weeks unless the company was not be relaunched imminently. However given the narrative here it's anyone's guess as to what happens.
Checked the portal this morning, still no update. Must be waiting for some news to trigger a review of their forecasts.
https://www.cnbc.com/amp/2018/11/01/illumina-buys-pacific-biosciences-for-1point2-billion-why.html
Zapping costs ... clearly needed given recent events. Need top notch sales people who buildc relationships and deliver the big stuff. You want people who still have drive, have something to lose and not on the AIM gravytrain.
In addition to the help that this gives to cost management I take this news as reorganisation before the Company relaunch which is good news. There has been a lot of potential news already forward trailed in some of the company presentations; such as Company Name/TDIM Change, reproductive health product news, TMO warrants conversion/debt forgiveness, and more detail on the revised company strategy etc. I would have to imagine that some of these would at the very least have an internal target to be released by Half Year results as it wouldn't make sense to have the Half Year report having another Company Name etc. So it will be interesting to see what else is achieved by then as well as to publicise relaunch. I suspect by now a revised Articles of Association for the Company is being prepared and we should hopefully get a timeline issued shortly to the Company relaunch.
I’m sure there will be more news but how and when is an unknown at the moment but I’m feeling optimistic about key announcements through November and December, with the Taiwan expo, interims and 3 year business plan all in the pipeline.
Having a dig through the Annual Report I found that Peter C invoiced Premaitha for circa £256k for ‘consultancy services’, so whilst this does not necessary correlate to his salary, it does give as an indication of the potential annual cost saving made with his departure.
Agreed, would be helpful to have this on their bios on the website. I was expecting more news flow since the placing but I guess AR’s purchase of more shares indicated there was nothing commercially sensitive to reveal at that time. Still I would expect more news of contract wins around the world and there is nothing hindering their announcement now the litigation is concluded. We need to build some momentum and as flipper says the coming weeks before the interim results would be the perfect time.
I would be keen to better understand the specific remits that Nick and Hayden both have to be honest because I can only limited conclusions using online information available.